Shahram Shahangian, Ph.D.; Ana K. Stanković, M.D., Ph.D.; Ira M. Lubin, Ph.D.;James H. Handsfield, M.P.H.; Mark D. White, B.S.
 

1. Brigden ML, Johnston M for the Thrombosis Interest Group of Canada. A survey of aPTT reporting in Canadian medical laboratories. The need for increased standardization. Thrombosis Interest Group of Canada. Am J Clin Pathol. 2000;114:276282. Abstract
    
2. Favaloro EJ, Thom J, Baker R for Australasian Society for Thrombosis and Haemostasis (ASTH) Emerging Technologies Group. Assessment of current diagnostic practice and efficacy in testing for von Willebrand's disorder: results from the second Australasian multi-laboratory survey. Blood Coagul Fibrinol. 2000;11:729737. Abstract
    
3. Favaloro EJ, Smith J, Petinos P, Colecutt M, Street A, Hertzberg M. Laboratory testing, diagnosis, and management of von Willebrand disease. Current practice in Australasia. RCPA. Quality Assurance Program in Haematology Scientific Haemostasis Advisory Panel. Am J Clin Pathol. 1999;112:712719. Abstract
    
4. Favaloro EJ, Smith J, Petinos P, Hertzberg M, Koutts J. Laboratory testing for von Willebrand's disease: an assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey. RCPA Quality Assurance Program (QAP) in Haematology Haemostasis Scientific Advisory Panel. Thromb Haemost. 1999;82:12761282. Abstract
    
5. Brigden ML, Johnston MJ. INR reporting in Canadian medical laboratories: an update. Thrombosis Interest Group of Canada. Am J Clin Pathol. 1998;109:589594. Abstract
    
6. Lum G. Critical limits (alert values) for physician notification: universal or medical center specific limits? Ann Clin Lab Sci. 1998;28:261271. Abstract
    
7. Murray ET, Fitzmaurice DA. An evaluation of quality control activity for near patient testing in primary care. Br J Gen Pract. 1998;48:18531854. Abstract
    
8. Graves DF, Chernin JM, Kurusz M, Zwischenberger JB. Anticoagulation practices during neonatal extracorporeal membrane oxygenation: survey results. Perfusion. 1996;11:461466. Abstract
    
9. Mackinlay N, Favaloro E, Arthur C, Smith J, Aboud M. A survey of heparin monitoring in Australasia. Pathology. 1996;28:343347. Abstract
    
10. Yim JM, Albers GW, Vlasses PH. Anticoagulant therapy monitoring with international normalized ratio at US academic health centers. Ann Pharmacother. 1996;30:13901395. Abstract
     
11. Andrew M, Brigden M, Bormanis J, Cruickshank M, Geerts W, Giles A, et al for the Thrombosis Interest Group of Canada. INR reporting in Canadian medical laboratories. Am J Hematol. 1995;48:237239. Abstract
     
12. Ansell JE. Imprecision of prothrombin time monitoring of oral anticoagulation. A survey of hospital laboratories. Am J Clin Pathol. 1992;98:237239. Abstract
     
13. Nelson DE. Current considerations in the use of the APTT in monitoring unfractionated heparin [Review]. Clin Lab Sci. 1999;12:359364. Abstract
     
14. Fairweather RB, Ansell J, van den Besselaar AM, Brandt JT, Bussey HI, Poller L, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of oral anticoagulant therapy [Review]. Arch Pathol Lab Med. 1998;122:768781. Accessed January 2003. Abstract, Full Text PDF
     
15. Laposata M, Green D, van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban [Review]. Arch Pathol Lab Med. 1998;122:799807.Accessed January 2003. Abstract, Full Text PDF
     
16. Olson JD, Arkin CF, Brandt JD, Cunningham MT, Giles A, Koepke JA, Witte DL. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy [Review]. Arch Pathol Lab Med. 1998;122:782798.Accessed January 2003. Abstract, Full Text PDF
     
17. Ansell JE, Buttaro ML, Thomas OV, Knowlton CH. Consensus guidelines for coordinated outpatient oral anticoagulation therapy management. Anticoagulation Guidelines Task Force [Review]. Ann Pharmacother. 1997;31:604615. Abstract
     
18. Adcock DM, Kressin DC, Marlar RA. Minimum specimen volume requirements for routine coagulation testing: dependence on citrate concentration. Am J Clin Pathol. 1998;109:595599. Abstract
     
19. Reneke J, Etzell J, Leslie S, Ng VL, Gottfried EL. Prolonged prothrombin time and activated partial thromboplastin time due to underfilled specimen tubes with 109 mmol/L (3.2%) citrate anticoagulant. Am J Clin Pathol. 1998;109:754757. Abstract
     
20. Adcock DM, Kressin DC, Marlar RA. Effect of 3.2% vs 3.8% sodium citrate concentration on routine coagulation testing. Am J Clin Pathol. 1997;107:105110. Abstract
     
21. Bussey HI, Force RW, Bianco TM, Leonard AD. Reliance on prothrombin time ratios causes significant errors in anticoagulation therapy. Arch Intern Med. 1992;152:278282. Abstract
     
22. NCCLS. How to Define and Determine Reference Intervals in the Clinical Laboratory; Approved GuidelineSecond Edition (Document C28-A2). Wayne, PA:NCCLS; 2000.
     
23. Watson C, Kitchen S, Woolley AM, Young L, Malia RG. Recombinant and tissue extract thromboplastins for determination of international normalised ratio in over-anticoagulated patients. Br J Biomed Sci. 1999;56:123127. Abstract
     
24. Baele G, Fiers T, Leroux-Roels G. Comparison of a recombinant thromboplastin with Thrombotest for oral anticoagulant control. Haemostasis. 1996;26:1115. Abstract
     
25. Davis KD, Danielson CF, May LS, Han ZQ. Use of different thromboplastin reagents causes greater variability in international normalized ratio results than prolonged room temperature storage of specimens. Arch Pathol Lab Med. 1998;122:972977. Abstract
     
26. Kitchen S, Jennings I, Woods TA, Walker ID, Preston FE. Two recombinant tissue factor reagents compared to conventional thromboplastins for determination of international normalised ratio: a thirty-three-laboratory collaborative study. The Steering Committee of the UK National External Quality Assessment Scheme for Blood Coagulation. Thromb Haemost. 1996;76:372376. Abstract
     
27. Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range [Review]. Chest. 1995;108(4 Suppl):231S246S.
     
28. Hobbs FD, Fitzmaurice DA, Murray ET, Holder R, Rose PE, Roper JL. Is the international normalised ratio (INR) reliable? A trial of comparative measurements in hospital laboratory and primary care settings. J Clin Pathol. 1999;52:494497. Abstract
     
29. Shojania AM, Tetreault J, Turnbull G. The variations between heparin sensitivity of different lots of activated partial thromboplastin time reagent produced by the same manufacturer. Am J Clin Pathol. 1988;89:1923. Abstract
     
30. Kitchen S, Jennings I, Woods TA, Preston FE. Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage. J Clin Pathol. 1996;49:1014. Abstract
     
31. Scialla SJ. Heparin monitoring by activated partial thromboplastin time. Comparison of ex vivo measurement and in vitro standardization. Am J Clin Pathol. 1985;84:351354. Abstract
     
32. College of American Pathologists. Comprehensive Coagulation Survey. Participant Summary (Set GC2-A). Northfield, IL: College of American Pathologists; 1995.
     
33. Smythe MA, Koerber JM, Westley SJ, Nowak SN, Begle RL, Balasubramaniam M, Mattson JC. Use of the activated partial thromboplastin time for heparin monitoring. Am J Clin Pathol. 2001;115:148155. Abstract
     
34. Adcock D, Kressin D, Marlar RA. The effect of time and temperature variables on routine coagulation tests. Blood Coagul Fibrinol. 1998;9:463470. Abstract
     
35. NCCLS. Collection, Transport and Processing of Blood Specimens for Coagulation Testing and General Performance of Coagulation Assays; Approved GuidelineThird Edition (Document H21-A3). Wayne, PA:NCCLS; 1998.
     
36. O'Donnell J, Boulton FE, Manning RA, Laffan MA. Genotype at the secretor blood group locus is a determinant of plasma von Willebrand factor level. Br J Haematol. 2002;116:350356. Abstract
     
37. Souto JC, Almasy L, Muniz-Diaz E, Soria JM, Borrell M, Bayen L, et al. Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. Arterioscl Thromb Vasc Biol. 2000;20:20242028. Abstract
     
38. Nitu-Whalley IC, Lee CA, Griffioen A, Jenkins PV, Pasi KJ. Type 1 von Willebrand diseasea clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history. Br J Haematol. 2000;108:259264. Abstract
     
39. Favaloro EJ, Koutts J. Laboratory assays for von Willebrand factor: relative contribution to the diagnosis of von Willebrand's disease. Pathology. 1997;29:385391. Abstract
     
40. Favaloro EJ. Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrands disease. Blood Rev. 1999;13:185204. Abstract,  Full Text
     
41. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA. 1997;277:13051307. Abstract
     
42. Hooper WG, Evatt BL. The role of activated protein C resistance in the pathogenesis of venous thrombosis [Review]. Am J Med Sci. 1998;316:120128. Abstract
     
43. Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med. 2001;3:139148. Abstract,  Full Text and PDF
     
44. Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med. 1999;130:643650. Abstract
     
45. Hille ET, Westendorp RG, Vandenbroucke JP, Rosendaal FR. Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated protein C). Blood. 1997;89:19631967. Abstract
     
46. Centers for Disease Control and Prevention. CLIA Subpart JPatient Test Management for Moderate Complexity (Including the Subcategory), High Complexity, or Any Combination of These Tests. Sec. 493.1109. Standard: Test report.  Accessed, December 2002.
     
47. Sage-el A, Burns E, Wenz B. The unwarranted use of replicate analysis in routine coagulation studies. Am J Clin Pathol. 1985;83:8183. Abstract
     
48.  Kramer G, Bradlow BA. An analysis of duplicate testing of prothrombin time and activated partial thromboplastin time assays. Am J Clin Pathol. 1991;95:7781. Abstract
     
49. Centers for Disease Control and Prevention. CLIA Subpart KQuality Control for Tests of Moderate Complexity (Including the Subcategory), High Complexity, or Any Combination of These Tests. Sec. 493.1253 Condition: Hematology.  Accessed, December 2002.
     
50. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med. 1998;158:16411647. Abstract
     
51. van Cott EM. Coagulation point-of-care testing. Clinics Lab Med. 2001;21:337350. Abstract
     
52. LaBeau KM, Granade S, Steindel SJ. The Pacific Northwest Laboratory Medicine Sentinel Monitoring Network Final report of the findings of Questionnaire 16: Use of the Internet.  Accessed, December 2002.
     
53. Bilder CR, Loughin TM. Testing for conditional multiple marginal independence. Biometrics. 2002;58:200208. Abstract